Literature DB >> 31567483

Transcriptomic analysis reveals that heat shock protein 90α is a potential diagnostic and prognostic biomarker for cancer.

Wei Chen1, Guanghua Li1, Jianjun Peng1, Weigang Dai1, Qiao Su2, Yulong He1,3.   

Abstract

The molecular chaperone heat shock protein 90 (Hsp90) is highly expressed in tumor tissue according to many studies. However, there is no large-scale study investigating the expression of Hsp90 in pan-cancer so far, and the molecular mechanisms leading to aberrant Hsp90 expression are also largely unknown. To address these questions, we performed an in silico analysis of Hsp90 expression using mRNA sequencing data from The Cancer Genome Atlas study. The results were further validated using independent datasets. We found that the expression of HSP90AA1, a subtype of Hsp90, was much higher in hepatocellular carcinoma than in adjacent normal liver tissue. A large cancer panel with eight more cancer types revealed a similar trend except for prostate cancer, which had low HSP90AA1 expression in tumor tissue. Heat shock factor 1 followed a similar trend as HSP90AA1, with higher expression in cancer. HSP90AA1 expression was closely related to its copy numbers. Deletion of the HSP90AA1 locus in a subset of hepatocellular carcinoma led to low HSP90AA1 expression. In addition, higher HSP90AA1 expression was associated with poorer prognosis in hepatocellular carcinoma patients. In a multivariable analysis including tumor, node and metastasis stage, HSP90AA1 expression remained a negative prognostic factor, suggesting that the effect of HSP90AA1 was independent of tumor stage. In conclusion, we demonstrated that high HSP90AA1 expression was ubiquitous in cancer and that HSP90AA1 was a potential diagnostic and prognostic biomarker for hepatocellular carcinoma.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 31567483     DOI: 10.1097/CEJ.0000000000000549

Source DB:  PubMed          Journal:  Eur J Cancer Prev        ISSN: 0959-8278            Impact factor:   2.497


  7 in total

1.  Patient-specific Boolean models of signalling networks guide personalised treatments.

Authors:  Julio Saez-Rodriguez; Laurence Calzone; Arnau Montagud; Jonas Béal; Luis Tobalina; Pauline Traynard; Vigneshwari Subramanian; Bence Szalai; Róbert Alföldi; László Puskás; Alfonso Valencia; Emmanuel Barillot
Journal:  Elife       Date:  2022-02-15       Impact factor: 8.713

2.  Protein expression profiling of rat uteruses with primary dysmenorrhea syndrome.

Authors:  Yazhen Xie; Jianqiang Qian; Mingmei Wu
Journal:  Arch Gynecol Obstet       Date:  2021-09-15       Impact factor: 2.344

3.  Gaining new insights on the Hsp90 regulatory network.

Authors:  Francesco Piva; Monia Cecati; Matteo Giulietti
Journal:  Bioinformation       Date:  2020-01-01

4.  Based on network pharmacology and molecular docking to predict the mechanism of Huangqi in the treatment of castration-resistant prostate cancer.

Authors:  Zesen Lin; Zechao Zhang; Xuejin Ye; Min Zhu; Zhihong Li; Yu Chen; Shuping Huang
Journal:  PLoS One       Date:  2022-05-20       Impact factor: 3.240

5.  miR-550a-3p is a prognostic biomarker and exerts tumor-suppressive functions by targeting HSP90AA1 in diffuse malignant peritoneal mesothelioma.

Authors:  Rihan El Bezawy; Stefano Percio; Chiara Maura Ciniselli; Michelandrea De Cesare; Gennaro Colella; Matteo Dugo; Silvia Veneroni; Valentina Doldi; Silvia Martini; Dario Baratti; Shigeki Kusamura; Paolo Verderio; Marcello Deraco; Paolo Gandellini; Nadia Zaffaroni; Valentina Zuco
Journal:  Cancer Gene Ther       Date:  2022-03-29       Impact factor: 5.854

6.  Oncogenic enhancers drive esophageal squamous cell carcinogenesis and metastasis.

Authors:  Bo Ye; Dandan Fan; Weiwei Xiong; Min Li; Jian Yuan; Qi Jiang; Yuting Zhao; Jianxiang Lin; Jie Liu; Yilv Lv; Xiongjun Wang; Zhigang Li; Jianzhong Su; Yunbo Qiao
Journal:  Nat Commun       Date:  2021-07-22       Impact factor: 14.919

7.  Characterization of diagnostic and prognostic significance of cell cycle-linked genes in hepatocellular carcinoma.

Authors:  Jukun Wang; Yu Li; Chao Zhang; Xin Chen; Linzhong Zhu; Tao Luo
Journal:  Transl Cancer Res       Date:  2021-11       Impact factor: 1.241

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.